Posted by Robert_Burton_1621 on July 24, 2015, at 17:57:22
In reply to Lou's response-shdahnownbedur, posted by Lou Pilder on July 24, 2015, at 17:09:39
> > Mr. Pilder.
> >
> > Your research seems to be incomplete. Please review the following article with special attention paid to the quoted passages. You simply do not know enough to go out of your way to scare people.
> >
> >
> > - Scott
> >
> > ----------------------------------------------------
> >
> > http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014120/
> >
> > "The data indicate that nortriptyline and desipramine have the most pharmacologically desirable characteristics as noradrenaline reuptake inhibitors (NRIs), and as drugs with few interactions that are also safe when coadministered with either MAOIs or SSRIs."
> >
> > "When tyramine is administered intravenously, blood pressure increases and this response is greatly potentiated by MAOIs. Tyramine utilizes, and requires, the NAT to enter the pre-synaptic terminal, where it then induces depolarization-independent release of NA. NRIs inhibit tyramine uptake and thus attenuate the response, which gives an in vivo measure of their NRI potency: indeed the NRIs with the highest affinity for the NAT (reboxetine, desipramine and nortriptyline; Table 3) have all been demonstrated to block this response almost completely, even when it has been potentiated in the presence of MAOIs"
> >
> > ----------------------------------------------------> Now the citation by Scott is concerning some tri-cyclic chemicals called antidepressants. This is not what the discussion concerns, for the discussion is about the interaction of Parnate and Strattera. Be not deceived here...
> And those of you that are going to accept Scott's portrayal of me as a person not knowing enough, and go ahead and take Parnate with Strattera, and are killed by the combination, it will be too late for you to think that you should have known better, and your blood will not be upon me.
> LouScott's description is accurate and objective. Your above post confirms it. The tricyclic medications which act as noradrenaline reputable inhibitors are many times more potent that strattera (whose pharmacological action is as an NRI). Why would it be safe to co-administer nortiptyline with tranylcypromine but not atomoxetine?
Your knowledge of MAOIs and their potential interactions is totally outdated, and inaccurate. The early reports of SAH deaths from MAOIs involved the consumption of tyramine-rich food like blue cheese, the combination of amphetamines with MAOIs, and serotonin toxicity when combined with serotonergic medications or extremely high levels of supplements (tryptophan).
Strattera is *not* a "stimulant" in the sense that, for instance, dextroamphetamine is.
If you cannot draw correct inferences from research which classifies medications by reference to their structure rather than pharmacological action (some "tricyclics" are just as much "serotonin reuptake inhibitors" as SSRIs - you are entirely mislead, and wrong, by thinking in terms of nominal categorisation), note these papers:
http://www.ncbi.nlm.nih.gov/pubmed/3997787
http://www.ncbi.nlm.nih.gov/pubmed/25884531
http://www.ncbi.nlm.nih.gov/pubmed/19067263
http://www.ncbi.nlm.nih.gov/pubmed/10901349
http://www.ncbi.nlm.nih.gov/pubmed/2710808?dopt=Abstract
http://www.ncbi.nlm.nih.gov/pubmed/24972362
I would like to echo Scott's admonishment: your persistence in alarming someone who is already in a difficult situation, without first fully assessing critically the cogency and accuracy of your warnings, is unjustifiable and very wrong.
poster:Robert_Burton_1621
thread:1080645
URL: http://www.dr-bob.org/babble/20150629/msgs/1080745.html